Results 1 to 10 of about 20,332 (170)

Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis [PDF]

Orphanet Journal of Rare Diseases, 2022
Background Non-Langerhans cell histiocytosis, including Erdheim–Chester disease (ECD), Rosai–Dorfman disease (RDD), indeterminate cell histiocytosis (ICH), and unclassified histiocytosis, is a rare disorder lacking a standard treatment strategy.
Ting Liu, Hua-cong Cai, Hao Cai, Miao Chen, Wei Zhang, Jian Li, Dao-bin Zhou, Xin-xin Cao   +7 more
doaj   +7 more sources

Intra-arterial Melphalan for Neurologic Non-Langerhans Cell Histiocytosis. [PDF]

Neurology, 2021
Histiocytic neoplasms are rare hematologic disorders characterized by pathologic infiltration of activated histiocytes in affected tissues. The treatment of histiocytic neoplasms, including Langerhans cell histiocytosis (LCH) and non-LCH, has advanced in recent years owing to targeted kinase inhibitors (BRAF and MEK) as patients with somatic mutations ...
Francis JH, Gobin YP, Alshiekh Nasany R, Knopman J, Ulaner GA, Panageas KS, Hatzoglou V, Salvaggio K, Abramson DH, Patsalides A, Diamond EL.   +10 more
europepmc   +5 more sources

A Rare Case of Erdheim-Chester Disease (Non-Langerhans Cell Histiocytosis) with Concurrent Langerhans Cell Histiocytosis: A Diagnostic and Therapeutic Challenge [PDF]

Case Reports in Hematology, 2018
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocyte disorder most commonly characterized by multifocal osteosclerotic lesions of the long bones demonstrating sheets of foamy histiocyte infiltrates on biopsy with or without histiocytic ...
Hamza Hashmi, Drew Murray, John Greenwell, Marwan Shaikh, Soumit Basu, Maxwell Krem   +5 more
doaj   +6 more sources

High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. [PDF]

Blood, 2017
Key Points Some 10.1% of adults with non–Langerhans cell histiocytosis have a concomitant myeloid neoplasm with each often harboring distinct mutations. The presence of distinct kinase mutations in histiocytosis and myeloid neoplasms resulted in discordant responses to targeted therapy.
Papo M, Diamond EL, Cohen-Aubart F, Emile JF, Roos-Weil D, Gupta N, Durham BH, Ozkaya N, Dogan A, Ulaner GA, Rampal R, Kahn JE, Sené T, Charlotte F, Hervier B, Besnard C, Bernard OA, Settegrana C, Droin N, Hélias-Rodzewicz Z, Amoura Z, Abdel-Wahab O, Haroche J.   +22 more
europepmc   +5 more sources

Successful Treatment of Non-Langerhans Cell Histiocytosis With Topical Rapamycin in Two Pediatric Cases [PDF]

Clinical, Cosmetic and Investigational Dermatology, 2022
Raden Mohamad Rendy Ariezal Effendi, Trustia Rizqandaru, Renata Yuliasari, Srie Prihianti Gondokaryono, Inne Arline Diana, Reiva Farah Dwiyana Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Dr.
Effendi RMRA, Rizqandaru T, Yuliasari R, Gondokaryono SP, Diana IA, Dwiyana RF   +5 more
doaj   +3 more sources

Case of Non-Langerhans Cell Histiocytosis in a Person Living with HIV - Clinical and Therapeutic Challenge [PDF]

Journal of the International Association of Providers of AIDS Care, 2022
Non-Langerhans cell histiocytosis is a rare disease which seldom affects adults. We report a case of a 32-year-old Bulgarian woman living with HIV. She developed severe anemia, extreme splenomegaly, requiring splenectomy and vertebral tumor formations ...
Nina Yancheva, Dimitar Strashimirov, Dragomir Dardanov, Bojidar Kamenov, Atanas Radinoff   +4 more
doaj   +4 more sources

Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis. [PDF]

Blood Adv, 2023
Key Points • MAPK alterations are a hallmark of ECD and RDD.• The MEK inhibitor trametinib is active in non-LCHs, including those without BRAF V600E mutations.
Aaroe A, Kurzrock R, Goyal G, Goodman AM, Patel H, Ruan G, Ulaner G, Young J, Li Z, Dustin D, Go RS, Diamond EL, Janku F.   +12 more
europepmc   +2 more sources

Disseminated non-Langerhans cell histiocytosis with an IRF2BP2-NTRK1 gene fusion identified by next-generation sequencing. [PDF]

JAAD Case Rep, 2020
DLBCL: diffuse large B-cell lymphoma ECD: Erdheim-Chester disease HCT: hematopoietic cell transplantation LCH: Langerhans cell histiocytosis NGS: next-generation sequencing PNH: progressive nodular histiocytosis STAMP: Solid Tumor Actionable Mutation ...
Chan WH, Shah A, Bae G, Hambro C, Martin BA, Brown R, Novoa R, Kwong BY.   +7 more
europepmc   +2 more sources

Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. [PDF]

Mol Cancer Ther, 2019
The BRAFV600E mutation and BRAF inhibitor responsiveness characterize ∼50% of patients with the non-Langerhans cell histiocytosis (non-LCH) Erdheim–Chester disease (ECD). We interrogated the non-LCH molecular landscape [ECD, n = 35; Rosai–Dorfman disease
Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R.   +9 more
europepmc   +2 more sources

Histiocyte Society blueprint for non-Langerhans cell histiocytosis research: unraveling complex diseases through collaboration. [PDF]

Haematologica
Histiocytic neoplasms are rare hematologic disorders characterized by pathological infiltration of myeloid-derived cells in various organs, resulting in diverse manifestations.
Hershkovitz-Rokah O, Abeykoon JP, Ravindran A, Goyal G.   +3 more
europepmc   +2 more sources